Latest News
- Aplagon Appoints Carl Lindgren as Board Chair to Guide Later Stage Clinical and Corporate Development 29 June 2026
- Aplagon Announces EUR 5 Million Financing to Broaden Phase 2 Trials of its APAC Therapy in Thrombo-Inflammatory Diseases 16 June 2026
- Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases 1 June 2026
- Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia 12 March 2026
- Aplagon Announces EUR 7 Million Financing to Advance its APAC Therapeutic for Thrombo-Inflammatory Diseases into Phase 2A Clinical Trials 3 February 2025
- First Patient Dosed in the CHASE Clinical Trial for Aplagon’s APAC Therapeutic for Thrombo-Inflammatory Diseases 24 October 2024
- Aplagon Signed EIC-Accelerator Grant Agreement 16 November 2022
- Aplagon Joins The TRACER Excellence Program to Perform In-Human Imaging Study 8 September 2022
- First Patient Treated in First Clinical Study for Aplagon’s APAC 7 June 2022
- Aplagon Publishes New Data in Prestigious Journal of Cardiovascular Pharmacology 1 September 2021
- Aplagon Closes Oversubscribed EUR 2.2M Funding Round 28 May 2021
- Aplagon Partners with Cadila Pharmaceuticals to Develop and Commercialize APAC First-in-Class Antithrombotics for the Prevention of Blood Vessel Occlusions Related to Vascular Interventions 19 September 2017
Events
Aplagon will be represented at the following partnering or scientific meetings.
There are currently no upcoming events
